Prevalence of colistin-resistant among carbapenem-resistant Acinetobacter baumannii isolates by minimal inhibitory concentration method
DOI:
https://doi.org/10.64149/J.Carcinog.24.2s.60-65Abstract
Introduction: Carbapenems, often considered antibiotics of last resort for treating multidrug-resistant infections, have been rendered ineffective against this pathogen in many cases, leading to the increased use of colistin as a treatment option.
Objective: To determine the prevalence of colistin resistant among carbapenem-resistant Acinetobacter baumannii isolates by minimal inhibitory concentration method.
Methodology: The prospective observational study was conducted over 24 months. The research was conducted at the Department of Microbiology at SGT University, Gurugram, and the Department of Microbiology at Pt. B.D. Sharma PGIMS, Rohtak. All consecutive, non-replicative clinical isolates of carbapenem-resistant Acinetobacter baumannii collected during the study period from both SGT University and Pt. B.D. Sharma PGIMS was included in the study. Clinical isolates were obtained from a variety of specimen types, including blood, sputum, urine, and wound swabs.
Results: Data were collected from 200 clinical isolates of Acinetobacter baumannii were 100% resistant to the carbapenem antibiotics tested, including imipenem, meropenem, and ertapenem. The study results revealed that 96% of the Acinetobacter baumannii isolates (192 out of 200) were susceptible to colistin, with MIC values below 4 µg/ml. However, 4% of the isolates (08 out of 200) exhibited colistin resistance, with MIC values equal to or greater than 4 µg/ml. This indicates that while colistin remains effective for the majority of isolates, a significant portion of carbapenem-resistant A. baumannii strains have developed resistance, posing a challenge for treatment options.
Conclusion: It is concluded that the prevalence of colistin resistance among carbapenem-resistant Acinetobacter baumannii (CRAB) isolates in this study was 4%, indicating a significant threat to the effectiveness of this last-resort antibiotic.
